EUVIMEDEUVIMED entdecken
Crossref

Use of Photon-Counting Detector CT to Visualize Liver-Specific Gadolinium-Based Contrast Agents: A Phantom Study

Stephan Rau, Thomas Stein, Alexander Rau, Sebastian Faby, Maximilian F Russe, Gregor Jost, Michael C Doppler, Friederike Lang, Fabian Bamberg, Hubertus Pietsch, Jakob Weiss

American Journal of Roentgenology · 2025

DOI: 10.2214/ajr.24.32434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Roentgenology, 2025. Verfasst von Stephan Rau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str 55, 79106 Freiburg…. Hauptthemen laut MEDLINE: Contrast Media, Tomography, X-Ray Computed, Gadolinium DTPA, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND. The low clinically approved doses of gadolinium-based contrast agents (GBCAs) do not generate sufficient enhancement on CT for diagnostic purposes. Photon-counting detector (PCD) CT offers improved spectral resolution and could potentially enable visualization of hepatocyte-specific GBCAs, given their associated high gadolinium concentrations within hepatocytes. OBJECTIVE. The purpose of this study was to investigate the potential of gadoxetate disodium in combination with PCD CT and low-energy virtual monoenergetic imaging (VMI) reconstructions to achieve an increase in attenuation in a phantom. METHODS. A series of solutions was prepared of diluted gadoxetate disodium (concentrations of 0.250-2.5 μmol/mL, corresponding with doses of 25-200 μmol/kg). These solutions, along with deionized water, were evaluated in an anthropomorphic abdominal phantom using a clinical PCD CT scanner; VMI reconstructions at 40, 50, 60, and 70 keV and virtual noncontrast (VNC) imaging reconstructions were generated. Attenuation measurements were obtained; a linear regression model combined these values with previously reported in vivo data to estimate hepatic enhancement and CNR across doses. RESULTS. Attenuation increased with increasing concentration at a given energy level and with decreasing energy level for a given concentration; VNC images had the lowest attenuation. The maximum attenuation reached in the abdominal phantom was 45.2 HU for a concentration of 2.5 μmol/mL at 40 keV. A concentration of 0.25 μmol/mL had attenuation at 40 keV of 13.0 HU. The model yielded estimated in vivo hepatic enhancement at 40 keV of 4.9 HU for a dose of 25 μmol/kg, 19.9 HU for 100 μmol/kg, and 30.8 HU for 200 μmol/kg; corresponding CNRs were 0.13, 0.52, and 0.81, respectively. CONCLUSION. The combination of gadoxetate disodium and PCD CT could theoretically allow appreciable hepatic enhancement at a 200-μmol/kg dose; such effect was not observed for the clinically approved 25-μmol/kg dose. CLINICAL IMPACT. PCD CT achieved attenuation increases for gadoxetate disodium at considerably lower doses than previously documented for CT of GBCAs, albeit at approximately eight times greater than clinical doses, which were thus too high for clinical use. Additional research exploiting PCD CT technology could seek to reduce further doses required for sufficient visualization into a clinically feasible range, to potentially allow CT using a liver-specific agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Contrast MediaTomography, X-Ray ComputedGadolinium DTPALiverPhantoms, ImagingHumansPhotons

Stichwörter der Autor:innen

contrast mediagadoliniumphoton-counting CTphoton-counting detectorsx-ray computed

Substanzen

Contrast Mediagadolinium ethoxybenzyl DTPAGadolinium DTPA

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str 55, 79106 Freiburg im Breisgau, Germany.
  • Department of Neuroradiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • CT, Siemens Healthineers, Forchheim, Germany.
  • MR and CT Contrast Media Research, Bayer Pharma, Berlin, Germany.

Zitieren

APA

Rau, S., Stein, T., Rau, A., Faby, S., Russe, M. F., Jost, G., Doppler, M. C., Lang, F., Bamberg, F., Pietsch, H., & Weiss, J. (2025). Use of Photon-Counting Detector CT to Visualize Liver-Specific Gadolinium-Based Contrast Agents: A Phantom Study. American Journal of Roentgenology. https://doi.org/10.2214/ajr.24.32434

Vancouver

Rau S, Stein T, Rau A, Faby S, Russe MF, Jost G, et al. Use of Photon-Counting Detector CT to Visualize Liver-Specific Gadolinium-Based Contrast Agents: A Phantom Study. American Journal of Roentgenology. 2025. doi:10.2214/ajr.24.32434

BibTeX
@article{Rau2025,
  author = {Rau, Stephan and Stein, Thomas and Rau, Alexander and Faby, Sebastian and Russe, Maximilian F and Jost, Gregor and Doppler, Michael C and Lang, Friederike and Bamberg, Fabian and Pietsch, Hubertus and Weiss, Jakob},
  title = {Use of Photon-Counting Detector CT to Visualize Liver-Specific Gadolinium-Based Contrast Agents: A Phantom Study},
  journal = {American Journal of Roentgenology},
  year = {2025},
  doi = {10.2214/ajr.24.32434}
}
Kostenlos starten →